Why Indomethacin Is Not Your Average Painkiller: the Hidden Power and Risks
By James H. Sterling
To understand why doctors prescribe indomethacin, one must look at how inflammation cascades through human tissue. Like all classic nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin blocks the cyclooxygenase enzymes, specifically COX-1 and COX-2. These enzymes convert arachidonic acid into prostaglandins, the lipid compounds responsible for triggering pain, swelling, fever, and capillary widening.
Indomethacin differentiates itself through sheer binding strength and additional cellular pathways. It suppresses prostaglandin synthesis with exceptional speed, while simultaneously inhibiting the movement of polymorphonuclear leukocytes into inflamed joints. In laboratory benchmarks, indomethacin shows roughly 10 to 40 times the anti-inflammatory potency of aspirin on a milligram-for-milligram basis.
That raw power explains why it remains a first-line clinical weapon when tissue inflammation threatens severe structural distress or becomes intolerable for the patient.
James Sterling reports on renewable energy developments, climate policy, ecological conservation, and green tech innovations around the globe.
